ASPPH logo


Member Research & Reports

Member Research & Reports

Vanderbilt Examines Type 2 Diabetes and Risk of Heart Attack, Stroke, or Death

In an observational study by researchers at Vanderbilt University Medical Center, adults with type 2 diabetes who take insulin in addition to the recommended first-line drug therapy, metformin, had a 30 percent higher risk of heart attack, stroke, or death when compared to similar patients who instead augment their metformin regimen with a sulfonylurea.

Christianne Roumie, MD and group at the VA hospital  by : Susan Urmy

[Photo: Vanderbilt MPH graduate Dr. Christianne Roumie, third from right, with study collaborators, from left, VU MPH graduate Dr. Adriana Hung, Dr. Robert Greevy, VU MPH program director Dr. Marie Griffin, Dr. Harvey Murff,  VU MPH graduate Dr. Carlos Grijalva, and Dr. Xulei Liu. (photo by Ms. Susan Urmy)]

New heart attacks and strokes occurred at similar rates in both groups, but death (from all causes) was 44 percent higher in patients who added insulin compared to those who added a sulfonylurea.

The study appeared this week in the Journal of the American Medical Association (JAMA), highlighted with an accompanying editorial and an online video interview with lead author Dr. Christianne Roumie, associate professor of medicine and pediatrics.

Dr. Roumie and colleagues compared medical records of two groups of Veterans Health Administration patients with diabetes: 2,436 who took metformin and insulin, and 12,180 who instead took metformin and one or another type of sulfonylurea. The research team accounted for patient co-morbidities, age, duration of treatment, smoking status, sex, race, and physiologic variables, including diabetes control.

Some 26 million Americans have diabetes (type 2 accounts for between 90 and 95 percent of all diabetes in the United States). Diet and exercise often provide an effective first-line intervention for this disease, but many patients require a medication, and metformin is recommended as a first-line treatment. Many patients eventually require additional medicines, and according to Dr. Roumie, the choice of a second medication has been less clear.

“A couple of small clinical trials have shown that using insulin earlier in a disease course helps preserve beta cells in your pancreas longer,” she said.

On the other hand, “multiple large clinical trials have found either no benefit or potential harm from attempting very tight management of glucose. We wanted to look within a real-world practice at the drugs that patients use and evaluate the outcomes.”

In a statement accompanying the study, Dr. Roumie wrote, “Although adding insulin seems a reasonable option for some patients who have very high glucose or who desire flexible and fast blood sugar control, the study findings suggest that for most patients who need a second diabetes drug, adding a sulfonylurea to metformin should be preferred to adding insulin.”

At present, any underlying mechanism that might explain the increased risk of death found in the study remains unknown.

Read more: